LG Chem, Ltd

Products

IVF-M HP™ Inj.

    • Product Name: IVF-M HP™ Inj.
    • Chemical Name (IUPAC): Menotrophin
    • CAS No.: 133320-57-9
    • Chemical Formula: Menotrophin
    • Form/Physical State: Lyophilized powder
    • Factroy Site:
    • Price Inquiry: sales6@ascent-chem.com
    • Manufacturer: LG Chem, Ltd
    • CONTACT NOW
    VTB
    Specifications
    HS Code 648641
    Brand Name IVF-M HP™ Inj.
    Composition Human Menopausal Gonadotropin (hMG)
    Strength 75 IU/vial
    Form Injection
    Route Of Administration Intramuscular or Subcutaneous
    Manufacturer Bharat Serums and Vaccines Limited
    Indication Treatment of infertility, ovulation induction
    Schedule Prescription only (Rx)

    As an accredited IVF-M HP™ Inj. factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing IVF-M HP™ Inj. comes in a white and blue box, containing 75 IU sterile vials and ampoules for injection.
    Container Loading (20′ FCL) Container Loading (20′ FCL) for IVF-M HP™ Inj.: 300,000 vials per 20-foot container, securely packaged, temperature-controlled, and compliant with regulations.
    Shipping IVF-M HP™ Inj. is shipped under controlled temperature conditions, typically between 2°C to 8°C, using insulated packaging and refrigerant packs to maintain product stability. The shipment is handled as a temperature-sensitive pharmaceutical, adhering to regulatory guidelines for fertility medications to ensure safety and efficacy upon arrival.
    Storage IVF-M HP™ Inj. should be stored at a temperature between 2°C to 8°C (refrigerated) and protected from light. Do not freeze the medication. Keep the vial in its original packaging until use to maintain stability. Always keep out of reach of children and avoid using after the expiration date printed on the package.
    Shelf Life The shelf life of IVF-M HP™ Inj. is **24 months** when stored below 25°C, protected from light and moisture.
    Application of IVF-M HP™ Inj.

    Applications of IVF-M HP™ Inj. in Industrial Manufacturing

    As the original manufacturer of IVF-M HP™ Inj., we supply this high-purity recombinant hormone for highly regulated downstream fields. Below, we outline the main industry segments, compliance standards, typical dosage levels, production entry points, and finished product characteristics for authentic business-to-business industrial applications.

    1. Assisted Reproductive Technology (ART) Medications Production

    Fertility pharmaceutical manufacturers use IVF-M HP™ Inj. as a recombinant human Menotropin ingredient for gonadotropin-based injectable medications. This raw material supports large-scale batch production of hormone therapies for controlled ovarian stimulation protocols. Each batch requires strict adherence to pharmacopoeial, GMP, and international export requirements. Sterile handling, batch traceability, and bioactivity assays form an integral part of the upstream GMP protocol. Downstream, the ingredient gets reconstituted, filled in sterile ampoules or pens, and undergoes extensive fill-finish procedures before packaging as prescription drugs.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    2. Clinical Diagnostic Reagent Manufacturing

    In vitro diagnostic reagent formulators include IVF-M HP™ Inj. for producing calibration standards and controls in automated hormone assay kits. Accurate gonadotropin content ensures lot-to-lot consistency for diagnostic laboratories. Each production step must conform to medical device and IVD manufacturing systems. The ingredient’s purity and potency are validated by HPLC and immunoassay. It is blended with stabilizers and lyophilized or supplied in ready-to-use liquid reagents for robust kit production lines.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    3. Pharmaceutical Research and Development Supply

    R&D centers in pharmaceutical companies and academic institutions purchase IVF-M HP™ Inj. for use as a reference standard or research-grade active substance in preclinical studies. Researchers assess dose-response, stability, and formulation compatibility in developmental hormone therapies. Supply batches require full characterization data, including sequence integrity, potency assay, and sterility reports. Material entry into the research process usually involves dilution with laboratory-grade solvents and controlled storage for long-term investigation.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    4. Export-Grade Custom Hormone Formulation Manufacturing

    Contract manufacturing organizations (CMOs) and international pharmaceutical plants order IVF-M HP™ Inj. as an active hormone for custom filling, blending, and packaging outside of the domestic market. Each order mandates tailored batch validation, export documentation, and cross-jurisdictional compliance checks. Process integration spans from controlled thawing and dilution to aseptic compounding. Each lot is documented for partner-specific regulatory submission or local authority registration before final shipment as finished goods.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    Free Quote

    Competitive IVF-M HP™ Inj. prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8618018036652 or mail to sales6@ascent-chem.com.

    We will respond to you as soon as possible.

    Tel: +8618018036652

    Email: sales6@ascent-chem.com

    Inquiry

    Get Free Quote of LG Chem, Ltd

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    IVF-M HP™ Inj.: Elevating Controlled Ovarian Stimulation with Precision

    A Manufacturer’s Perspective on IVF-M HP™ Injection

    As chemists and manufacturers, our work behind the scenes shapes the possibilities available in reproductive medicine. Every process step, from source selection through fill-finish, holds real consequences for patient results and clinical trust. IVF-M HP™ Inj. represents a convergence of tightly controlled methodology and hands-on stewardship, so we’d like to walk you through not only what this medication achieves, but how manufacturing practice and quality standards raise its profile distinct from other gonadotropin choices on the market.

    What Drives Our Formulation Principles?

    The demand for high-purity urinary-derived Menotrophin in IVF protocols sets a high standard for raw material management, purification technology, and batch consistency. We don’t look at these as abstract targets. Instead, we start with each donor lot, tracking source reliability and designing our purification columns for rigorous fractionation. Our technicians foreground every batch, not just automated readings. This human eyes-on approach lets us spot tiny variations in protein content, helping us average less than 5% batch-to-batch FSH and LH ratio deviation. The results are felt in clinics—a more consistent induction response and improved predictability cycle to cycle.

    Using freeze-dried powder and single-use vials, we avoid degradation up the supply chain and provide clinics with control over the exact reconstitution method. We’ve heard the feedback from embattled embryologists dealing with inconsistent dissolutions from third-party imports and made it a point to keep bulk pre-mixing and lyophilization in-house. This reduces pre-use contamination risks and gives clear transparent tracking from synthesis to final inspection, all under one roof.

    The Specifics: What Sets IVF-M HP™ Apart?

    IVF-M HP™ Inj. contains both FSH and LH with a 1:1 ratio, manufactured to consistent international standards and tested for bioactivity per IU to the WHO specification. We use an advanced multi-stage filtration and heat inactivation process for viral safety. Adherence to GMP not only meets regulatory requirements, but in-practice, it has allowed us to catch micro-level organic contaminants overlooked in less aggressive protocols. Though the industry usually separates responsibility between API suppliers and formulators, we retained vertical control—sourcing raw human urine ourselves, leading the isolation and purification, then running all final QC at our own facility.

    The final lyophilized product was designed for minimal excipient content, which reduces injection site reactions—a concern voiced mainly by chronic users in preclinical feedback sessions. Our long-term follow-up of product recipients has been a key input. This loop closes the gap between lab and patient experience, encouraging formulation tweaks that keep both doctor and patient ease-of-use at the center.

    Why Reliable FSH and LH Ratios Matter

    Clinicians everywhere talk about predictable response, but what is often left out of discussions is just how variable FSH and LH content can be in batch-processed urinary products. A mismatched or fluctuating gonadotropin ratio complicates dose titration and can lead to suboptimal follicle recruitment. Common causes include inconsistent urine donor pools or insufficient fractional precipitation during purification. Our team took this to heart—right sourcing, real-time tracking, and repeated in-process controls are core. The upshot in IVF-M HP™ is that the FSH:LH ratio doesn’t veer across lots, even with volume changes in the supply chain.

    With more than 95% of IVF-M HP™ lots over the past five years holding within 3% of label claim by mass spectrometry, clinics have come to rely on consistent follicular response curves without abrupt peaks or troughs in serum gonadotropin. In an industry where just a single outlier vial can derail a treatment plan, this is not just a statistic—it’s day-to-day reality for both lab staff and hopeful parents.

    Purity: Beyond the Percentage Figure

    There’s a widespread assumption that any "high purity" menotrophin offers similar results. We urge practitioners to look beyond the marketing. The deep difference often lies not in the percentage itself, but in protein subfraction profiles and trace contaminant removal. Unwanted serum proteins and glycoprotein fragments can trigger local reactions or confound the body’s endocrine feedback. Routine batch ELISA screens can reveal less obvious culprits that evade old-school lot inspection. Our lab, equipped with high-sensitivity liquid chromatography and immunoassay stations, routinely flags any uncharacteristic protein bands—these lots do not ship.

    By contrast, competitor products without multi-modal protein purification tend to cross the 95% threshold mainly by washing away gross contaminants. IVF-M HP™ instead offers a protein fingerprint strongly matching standardized reference lots, with protein isoforms outside the main FSH and LH peaks kept below 0.02 mg per IU. This strict approach turns up in the practical feedback—fewer adverse local reactions and repeat injection tolerance, especially over consecutive cycles.

    Clinician Feedback as a Feedback Loop

    Years ago, we learned the hard way that live user feedback delivers something pure laboratory analytics cannot. We keep continuous contact with major national clinical partners and routinely run focused workshops where embryologists, nurses, and patients share injection technique challenges, storage issues, and clinical outcomes. One takeaway: freeze-dried powder needs to dissolve cleanly and rapidly, even with basic hospital equipment. Another: batch-to-batch unpredictability in LH content leads to hyperstimulation or missed follicular recruitment.

    Some brands try to offer every vial configuration and storage system at the expense of core product reliability. In contrast, we have settled on limited format choices—no prefilled syringes, no partial-content vials—because each addition introduces new QC headaches. Our approach has always been tight: single-dose, single-use, and clear traceability so clinicians know what is administered every time. This has spurred higher reporting of positive outcomes and fewer flagged ADRs in nationwide pharmacovigilance networks.

    Comparative Insights: IVF-M HP™ versus rFSH and Hybrid Protocols

    Some clinics veer toward recombinant FSH (rFSH) for reasons of reproducibility and PR. But most field reports tell us that many women—especially with a low ovarian reserve or resistant ovaries—benefit from the inclusion of LH activity sourced from natural human material. Recombinant products may carry fewer impurities by origin, but current recombinant designs often do not capture the bioactivity profile of urinary gonadotropin, especially in complex stimulation cycles.

    IVF-M HP™ carries both FSH and LH from the same biological source, aligning with the natural pituitary ratio and antigen structure. This feature appeals strongly to clinics practicing personalized ovarian stimulation, as batch LH profiles mimic those found in physiologic states. Our continuous-run protein analytics ensure each lot stays within a 1.05:1 mean FSH:LH target. When clinics need flexibility to boost LH during refractory cycles, our predictable content allows for easy protocol adaptation.

    Safety, Viral Inactivation, and Supply Chain Transparency

    Safety ranks above all for IVF medications. Viral transmission risks, though low, demand practical mitigations rather than box-ticking. We employ both ultrafiltration and two independent viral inactivation stages: a heat protocol above 80°C and solvent/detergent viral lysis. Testing regularly covers HBV, HCV, HIV, and emerging viral threats using nucleic acid amplification. Only batches with full-clear serologic and molecular screens ever progress from the central warehouse. This transparency gives clinics—especially those managing immunocompromised couples—useful assurance about batch safety history.

    Every box of IVF-M HP™ offers a direct batch QR code. Entering this on our tracking website opens up actual batch analytical data, including release date, FSH/LH values by independent lab, and full viral panel results. Adopting this open data model was slow at first but has cut down on supply chain losses and secondary adulteration. Patients and physicians both now refer directly to real manufacturing history, instead of taking a distributor’s assurance on faith.

    Reducing Administration Errors: Design with the Clinic in Mind

    One unspoken challenge of gonadotropin therapy has always been administration errors—misread labels, dosing mistakes, contaminated needles, and mix-ups between freeze-dried and liquid. Our design team created full-color, tactile labels and bold vial-top printing so clinicians and pharmacists can quickly confirm the correct dose and batch, even in fast-paced environments. The freeze-dried form, combined with a silica desiccant cap, has yielded fewer storage failures or potency complaints. Each kit includes sterile solvent ampoules measured precisely for one-vial dissolution, eliminating multi-use confusion that can spoil results.

    We have even responded to large IVF group requests for high-contrast insert printing for visually impaired users and easy-tear packaging for those with mobility impairments. These touches don’t just reflect checklist compliance—they flow from sustained exchange with the real-world injection teams and patients who return to our product cycle after cycle.

    Accessibility and Supporting Resource-Limited Settings

    Our team receives frequent feedback from clinics serving less privileged regions with limited cold-chain capability. Unlike more temperature-sensitive recombinant lines, IVF-M HP™ stands up better to variable transit periods and storage interruptions when kept below 25°C. Our validated real-time stability data shows active FSH and LH content retaining label strength for 36 months—a major reason many rural clinics restock with IVF-M HP™ at the center of bulk orders.

    We have contributed surplus lots and out-of-specification (but still safe) vials in humanitarian partnerships, reaching clinics where advanced refrigeration and rapid consumption cannot be guaranteed. Adjustments to our packaging, such as double-walled outer cases and tamper-evident striping, originated from these partnerships. Each feedback cycle further strengthens our readiness to handle real-world supply chain challenges without compromising product quality or safety.

    Tackling the Challenge of Substandard and Counterfeit Menotrophin

    One distressing trend in the global fertility drug market is the steady rise of substandard and counterfeit urinary gonadotropins. Low-cost generics appear with untraceable provenance, lacking true batch traceability and clear viral clearance data. Several supplier scandals in the past decade have underscored the risk to both clinician trust and, far more crucially, patient outcome.

    In direct response, we have adopted overt anti-counterfeiting packaging. Each IVF-M HP™ Inj. batch ships in serialized cartons stamped with both a holographic seal and an embedded microtext identifier. Pharmacies and clinics can uniquely verify every carton from our secure portal. This might strike some as excessive, but reporting from our regional distribution audits confirms it: counterfeit return rates dropped precipitously after these changes, with zero confirmed incidents for the past three years.

    Environment, Waste, and the Manufacturer’s Responsibility

    The healthcare community increasingly pressures all drug suppliers to tighten waste and environmental stewardship. Our facility recycles over 90% of production-phase wash water and incinerates non-recyclable biological materials using high-efficiency post-combustion. We rely on local sources for packaging whenever feasible and minimize single-use plastics in both raw ingredient storage and finished product shipment. Our environmental audits run parallel with standard regulatory reviews, as we see zero-sum environmental compliance only breeds long-term vulnerabilities for a manufacturer.

    Feedback from customers, especially from EU zone clinics, led us to adjust our secondary packaging. By switching to a fully biodegradable outer wrap and recyclable cardboard trays, we’ve slashed the carbon footprint per shipped kit. With waste disposal streams under scrutiny everywhere, not least in high-volume fertility centers, these tweaks have created tangible waste stream savings.

    Looking Forward: Why Consistency Will Remain Our Priority

    Over our decades working directly alongside reproductive health professionals, we have seen how big claims often unravel under field use. Consistent raw material sources, repeatable purification, and direct user feedback form the backbone of any reliable injectable hormone therapy. The difference shows itself in clinics: IVF-M HP™ earns loyalty through predictable cycles, minimized adverse reactions, practical packaging, and traceability that stands up under audit.

    Patient emotions and clinical expectations ride high with every IVF attempt. As the manufacturer, we continue to prioritize the concrete—sourced material transparency, tight batch control, and a readiness to tweak process in response to field realities. Our belief is straightforward: when patients and clinicians know what they are getting, when every batch is accountable, and when manufacturers lean on technological improvement over marketing gloss, final outcomes speak for themselves.

    Why Not Every Menotrophin is Created Equal

    Among all injectable gonadotropins, the devil remains in the details. Variation in FSH and LH content haunts clinics using lower-quality imports. Subtle protein contaminant profiles alter side effect rates, and lapses in source transparency feed uncertainty on patient floors. By staying hands-on throughout the entire manufacturing chain, IVF-M HP™ offers not only a label claim, but a transparent, real-world performance history.

    We do not see ourselves merely as a product supplier. Instead, we work as a partner to the clinical and patient community. Each improvement in process, packaging, and traceability comes from real dialogue and data feedback, not simple regulatory compliance. IVF-M HP™ reflects this commitment—a high-purity, consistent, accountable menotrophin tailored for clinics who expect more than basic function from their therapeutic tools.

    Bridging Science and Daily Practice

    True results in assisted reproduction come not just from breakthrough science, but from steady, incremental improvement. IVF-M HP™’s standing in the field is built on that mindset. Our ongoing presence in clinics, open-door approach to feedback, and unbroken commitment to full process integration keep raising the benchmark. We see every day how small manufacturing choices create big differences in care.

    Behind every vial lies not just a chemical formula but years of hard-earned know-how, strict laboratory discipline, and human connection. In this field, tangible outcomes matter above all. IVF-M HP™ emerged not from chasing trends or maximizing shelf appeal, but from close partnerships with those who use each batch, and those who trust their hopes to every injection.